Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~All subjects:~* Able to attend all scheduled visits and to comply with all trial procedures.~Children/Adolescents aged ≥ 2 years to \< 18 years:~* Aged ≥ 2 years to \< 18 years on the day of inclusion.~* Informed Consent Form signed by one parent or another legal representative and by an independent witness if the parent/legal representative is illiterate.~* For a female, inability to bear a child or negative urine pregnancy test (as applicable).~* For a female of child-bearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination and at least 4 weeks after the last vaccination (as applicable).~Infants/toddlers aged ≥ 6 months to \< 2 years:~* Aged ≥ 6 months to \< 2 years on the day of inclusion.~* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2 kg.~* Informed Consent Form signed by one parent/legally acceptable representative and an independent witness if the parent/legally acceptable representative is illiterate.~* Subject who completed vaccination according to the national immunization schedule.~Exclusion Criteria :~All subjects:~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy.~* Systemic hypersensitivity to any of the vaccine components or history of life threatening reaction to the trial vaccine or a vaccine containing the same substances (egg proteins, chick proteins, thimerosal, aluminum, neomycin, formaldehyde, and octoxinol 9).~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Blood or blood-derived products received in the past 3 months.~* Any vaccination in the 4 weeks preceding the first trial vaccination.~* Vaccination planned in the 4 weeks following any trial vaccination.~* History of the H5N1 infection (confirmed either clinically, serologically or virologically).~* Known HIV, Hepatitis B (HBsAg) or Hepatitis C seropositivity.~* Previous vaccination with an avian flu vaccine.~* Subject at high risk of the H5N1 infection during the trial.~* Thrombocytopenia or bleeding disorder contraindicating IM vaccination.~* Febrile illness (rectal equivalent temperature ≥ 38.0°C) on the day of inclusion.~Children/Adolescents aged ≥ 2 years to \< 18 years:~* Breast-feeding mothers.~* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures (if applicable, depending on the subject's age).~Infants/toddlers aged ≥ 6 months to \< 2 years:~* History of seizures.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Subjects aged 9 to 17 years
- Study Group 2 (Type: EXPERIMENTAL): Subjects aged 3 to 8 years
- Study Group 3 (Type: EXPERIMENTAL): Subjects aged 6 to 35 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete